Autologous T Cell Expansion for PML Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an effective treatment for Progressive Multifocal Leukoencephalopathy (PML), a rare and usually fatal viral disease caused by the human polyomavirus JC virus, particularly in immunocompromised patients, as current therapies are limited and there are no approved treatments.
Innovation Solution
Administering a population of T cells that are activated and expanded in vitro using agents that stimulate the TCR/CD3 complex-associated signal and CD28 accessory molecule, such as anti-CD3 antibodies or superantigens, to induce proliferation, which are then infused into patients to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cells are activated and expanded using anti-CD3 antibodies or superantigens to treat PML, then the immune response against JC virus is enhanced, but the complexity of the treatment protocol increases
Solution Approach 1:
T cells are activated and expanded in vitro before administration to the patient. This preliminary action allows the immune cells to be prepared and multiplied outside the body, ensuring a sufficient number of activated T cells are available to combat the JC virus effectively when administered
Solution Approach 2:
Anti-CD3 antibodies or superantigens serve as intermediaries to activate T cells. These molecules mediate the activation signal by binding to CD3 receptors on T cells, triggering the immune response without requiring direct exposure to the JC virus during the activation phase
2Productivity
If T cells are stimulated with multiple agents (TCR/CD3 complex-associated signal and CD28 accessory molecule), then T cell proliferation is enhanced, but the manufacturing process complexity increases
Solution Approach 1:
Multiple stimulation signals (TCR/CD3 complex-associated signal and CD28 accessory molecule signal) are combined in a single in vitro culture system. This merging of multiple activation pathways into one integrated manufacturing process enhances T cell proliferation while streamlining the production protocol
Solution Approach 2:
The manufacturing process utilizes changes in stimulation parameters (adding both TCR/CD3 signal and CD28 signal) to optimize T cell proliferation. By adjusting these biochemical parameters in the culture medium, high-level T cell expansion is achieved through controlled parameter optimization rather than complex mechanical processes
Data Source
AI summary
The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.